449 related articles for article (PubMed ID: 37510993)
1. Innate Immunity in Cancer Biology and Therapy.
Zhang Y; Xue W; Xu C; Nan Y; Mei S; Ju D; Wang S; Zhang X
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510993
[TBL] [Abstract][Full Text] [Related]
2. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
3. Helper innate lymphoid cells as cell therapy for cancer.
Magnusson FC; Bahhar I
Immunology; 2023 Apr; 168(4):569-579. PubMed ID: 36288454
[TBL] [Abstract][Full Text] [Related]
4. Eosinophils in the tumor microenvironment: implications for cancer immunotherapy.
Ghaffari S; Rezaei N
J Transl Med; 2023 Aug; 21(1):551. PubMed ID: 37587450
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
6. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
7. Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy.
Lee D; Huntoon K; Wang Y; Jiang W; Kim BYS
Adv Mater; 2021 Jul; 33(27):e2007576. PubMed ID: 34050699
[TBL] [Abstract][Full Text] [Related]
8. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
9. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
11. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
14. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
Kim K; Yang WH; Jung YS; Cha JH
BMB Rep; 2020 Nov; 53(10):512-520. PubMed ID: 32731915
[TBL] [Abstract][Full Text] [Related]
15. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
16. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
17. Dawn era for revisited cancer therapy by innate immune system and immune checkpoint inhibitors.
Kim HD; Yeh CY; Chang YC; Kim CH
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167019. PubMed ID: 38211726
[TBL] [Abstract][Full Text] [Related]
18. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
19. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]